It is well known that ER-positive/HER2-negative breast cancers present lower pCR rates than triple-negative breast cancers when treated with neoadjuvant chemotherapy [31], and a retrospective study showed that a low percentage of ER expression is associated with a high pCR rate. The gene discussed is ERBB2; the disease is breast cancer.